例によりHOTLINEセッションの一覧がなかなか入手できないのでとりあえず。

URLはこちら　今年のHOTLINEも10ですね！

https://esc365.escardio.org/esc-congress/programme?text=&docType=All&days&session_type=Hot%20Line&page=1&vue=cards

 

HOT LINE 1 – August 29, 11:00 – 12:00
  • POTCAST – a Randomized Controlled Trial of Arrhythmia prevention using targeted plasma potassium levels in ICD Patients
    • Speaker: Christian Jons (Rigshospitalet – Copenhagen University Hospital – Copenhagen, Denmark)
  • AMALFI: Active Monitoring for Atrial Fibrillation
    • Speaker: Louise Bowman (University of Oxford – Oxford, UK)
  • DIGIT-HF: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction
    • Speaker: Udo Bavendiek (Hannover Medical School – Hannover, Germany)
  • DOUBLE-CHOICE: Anesthesia strategies and self-expanding valve types for TAVI
    • Speaker: Mohamed Abdel-Wahab (Heart Center of Leipzig – Leipzig, Germany)
HOT LINE 2 – August 30, 8:15 – 9:45
  • DAPA ACT HF-TIMI 68: Dapagliflozin in Patients Hospitalized for Acute Heart Failure
    • Speaker: David Berg (Brigham and Women’s Hospital – Boston, USA)
  • VICTOR: Vericiguat Global Study in Participants with Chronic Heart Failure and VICTORIA: Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction
    • Speakers: Faiez Zannad (University of Lorraine – Vandoeuvre-Les-Nancy, France) and Javed Butler (Baylor Scott & White Health – Dallas, USA).
  • ODYSSEY-HCM: Mavacamten in nHCM
    • Speaker: Milind Desai (Cleveland Clinic – Cleveland, United States)
  • MAPLE-HCM: aficamten vs metoprolol in oHCM
    • Speaker: Pablo Garcia-Pavia (Hospital Universitario Puerta de Hierro Majadahonda – Majadahonda, Spain)
HOT LINE 3 – August 30, 11:00 – 12:00
  • REBOOT-CNIC: betablockers after infarction with LVEF greater than 40%
    • Speaker: Borja Ibanez (National Center for Cardiovascular Research CNIC AND Fundacion Jimenez Diaz Hospital – Madrid, Spain)
  • THE BETAMI-DANBLOCK TRIAL: RANDOMIZED DISCONTINUATION OF BETA-BLOCKERS AFTER MYOCARDIAL INFARCTION
    • Speaker: Dan Atar (Oslo University Hospital Ulleval – Oslo, Norway)
  • REBOOT/BETAMI/DANBLOCK/CAPITAL-RCT: Beta-Blockers after MI with Mildly Reduced EF (an IPD meta-analysis)
    • Speaker: Francisco Javier Rossello (Son Espases University Hospital – Palma de Mallorca, Spain)
  • REFINE ICD: Efficacy of ICD therapy in higher risk post-MI patients with better-preserved LV function
    • Speaker: Derek Exner (Libin Cardiovascular Institute Of Alberta – Calgary, Canada)
HOT LINE 4 – August 30, 4:15 PM – 5:15 PM
  • BaxHTN – Efficacy and safety of the aldosterone synthase inhibitor baxdrostat in patients with uncontrolled or resistant hypertension
    • Speaker: Bryan Williams (University College London – London, UK)
  • KARDIA-3: Zilebesiran as Add-on Therapy in Adults with Hypertension and Established Cardiovascular Disease or at High Cardiovascular Risk
    • Speaker: Neha Pagidipati (Duke Clinical Research Institute – Durham, USA)
  • Essence-TIMI 73b
    • Speaker: Brian Bergmark (TIMI Study Group, Brigham and Women’s Hospital, Harvard Medical School – Boston, United States)
  • VICTORION-Difference study: Inclisiran-based strategy vs standard of care
    • Speaker: Ulf Landmesser (German Heart Center Berlin – Berlin, Germany)
HOT LINE 5 – August 30, 5:30 PM – 6:30 PM
  • DANCAVAS 2: Screening and intervention to prevent cardiovascular disease and death
    • Speaker: Axel Cosmus Pyndt Diederichsen (Odense University Hospital – Odense, Denmark)
  • PREVENT-MINS trial: Ivabradine for Prevention of Myocardial Injury After Noncardiac Surgery
    • Speaker: Wojciech Szczeklik (Jagiellonian University Medical College – Krakow, Poland)
  • ABC-AF study – a randomized controlled study of personalized treatment to reduce stroke or death in atrial fibrillation
    • Speaker: Jonas Oldgren (Uppsala University – Uppsala, Sweden)
  • HI-PRO: Apixaban for Extended Treatment of Provoked Venous Thromboembolism
    • Speaker: Gregory Piazza (Brigham and Women’s Hospital – Boston, USA)
HOT LINE 6 – August 31, 8:15 – 9:45
  • SWEDEPAD 1 and 2: Impact of drug-coated devices in patients with peripheral arterial disease
  • The PULSE randomized controlled trial
    • Speaker: Ovidio De Filippo (City of Health – Turin, Italy)
  • The AQUATIC trial
    • Speaker: Martine Gilard (Hospital Cavale Blanche – Brest, France)
  • The DUAL-ACS Trial: Duration of DAPT in ACS
    • Speaker: David Newby (University of Edinburgh – Edinburgh, UK)
  • OPTION-STEMI: Timing of complete revascularization during index hospitalization in patients with STEMI and multivessel disease
    • Speaker: Youngkeun Ahn (Chonnam National University Hospital – Gwangju, South Korea)
HOT LINE 7 – August 31, 4:15 PM – 5:15 PM
  • NEO-MINDSET: Early withdrawal of aspirin after percutaneous coronary intervention for acute coronary syndrome
    • Speaker: Pedro Lemos (Hospital Israelita Albert Einstein – Sao Paulo, Brazil)
  • TAILORED-CHIP: Tailored Antiplatelet Therapy for Complex High-Risk PCI
    • Speaker: Duk-Woo Park (Asan Medical Center – Seoul, South Korea)
  • TARGET-FIRST: Early aspirin discontinuation after PCI in acute MI patients
    • Speaker: Giuseppe Tarantini (University of Padua – Padua, Italy)
  • DAPT-SHOCK-AMI trial, Cangrelor in cardiogenic shock
    • Speaker: Zuzana Motovska (Third Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady – Prague, Czech Republic)
HOT LINE 8 – 31 August, 5:30 – 6:30 PM
  • ALONE-AF: Discontinuing long-Term oral anticoagulation after successful atrial fibrillation ablation
    • Speaker: Boyoung Joung (Yonsei University – Seoul, South Korea)
  • BEAT PAROX AF: a randomized comparison of PFA vs RFA
    • Speaker: Pierre Jais (IHU Liryc – Bordeaux, France)
  • CUVIA-PRR: Digital twin-guided rotor ablation for persistent atrial fibrillation
HOT LINE 9 – September 1, 8:15 – 9:45
  • PARACHUTE-HF: Randomized trial comparing sacubitril/valsartan with enalapril in patients with HFrEF caused by chronic Chagas cardiomyopathy
    • Speaker: Renato Lopes (Duke University Medical Center – Durham, USA)
  • HELP-MI SWEDEHEART – Randomized H. pylori screening after MI
    • Speaker: Robin Hofmann (Karolinska Institute – Stockholm, Sweden)
  • Project MHYH: One-Year Results
    • Speaker: Thomas Crawford (University of Michigan – Ann Arbor, USA)
  • IMPACT-BP Implementation of a Combination Intervention for Sustainable Blood Pressure Control in rural South Africa
    • Speaker: Thomas Andrew Gaziano (Brigham and Women’s Hospital and Brigham Health – Boston, United States)
HOT LINE 10 – September 1, 1:45 PM – 3:00 PM
  • NEWTON-CABG CardioLink-5: Evolocumab and Saphenous Vein Graft Patency
    • Speaker: Subodh Verma (St. Michael’s Hospital – Toronto, Canada)
  • TACSI: Dual or single antiplatelet therapy after CABG in patients with acute coronary syndrome
    • Speaker: Anders Jeppsson (Sahlgrenska University Hospital – Gothenburg, Sweden)
  • The TOP-CABG trial
    • Speaker: Xin Yuan (State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular D – Beijing, China)
  • OPINION Trial: 1-Year Outcomes
    • Speaker: Yang Wang (State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular D – Beijing, China)